glp-1 news oct 9 2025 ISPOR 2025: Exploring reasons for discontinuation glp-1 news october 9 2025

The current clinical evidence of intravenous glutathione for skin lightening is limited to a single study with a dubious study design and apparently flawed analysis of results, casting doubt on the drug's efficacy and reported adverse effects, with no evidence to prove its efficacy.There was only one placebo-controlled study on intravenous glutathione showing 37.5% response versus 18.7% placebo, and IV glutathione is contraindicated due to lack of efficacy and side effects

It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists , which were originally developed for type 2 diabetes management but have proven highly effective for weight loss

Similarly, individuals with certain blood cancers may present with unexplained weight loss, night sweats, or lymphadenopathy

Expression of NF-B has been shown to promote cell proliferation, whereas inhibition of NF-B activation blocks cell proliferation [179]